VisMederi

VisMederi is an Italian research and service company headquartered in Siena, founded in June 2009 as a spin-off of the Department of Molecular Medicine at the University of Siena. It positions itself as a globally competent, science-driven partner to corporations and the pharmaceutical industry, helping to accelerate the licensure of safer, more effective drugs. Its core business spans serological and cell-mediated immunity assays used to evaluate the immunogenicity of vaccines, the creation and validation of bioanalytical methods, and the optimization of experimental protocols for the assessment of biologicals and therapeutic molecules. The company delivers clinical and pre-clinical sample testing for the evaluation of vaccines, monoclonal antibodies, and antiviral therapeutics across all stages of drug development, from pre-clinical studies through Clinical Phases I–IV. Beyond analytical testing, VisMederi offers specialized central laboratory services supporting immunogenicity and efficacy programs for vaccines and therapeutics, acting as a focused laboratory partner that combines scientific leadership with targeted operational support to deliver harmonized data across multicentre studies. Laboratory activities are performed in fully equipped BSL2, BSL2+, and BSL3 environments, enabling comprehensive bioanalytical services that meet high scientific and regulatory standards. VisMederi operates under a certified Quality Management System and GCLP standards, developing, validating, and performing assays in alignment with EMA, FDA, and PMDA expectations to ensure regulatory-ready data. Its stated differentiators include scientific expertise in immunology and vaccine development, quality and compliance, reliable and reproducible results, and flexibility and speed in adapting to evolving project needs and timelines. VisMederi is a private company. Its founder, Emanuele Montomoli, serves as Founder and Chief Scientific Officer, while Duccio Meiattini is Chief Executive Officer. The company describes itself as rooted in Siena while reaching the world, serving pharmaceutical and biotech partners internationally. Its motto, "We prove. You improve.", reflects its role as a laboratory and scientific services provider supporting clients' drug development programs.

VisMederi was founded in June 2009 as a spin-off of the Department of Molecular Medicine at the University of Siena. From its base in Siena, the company rapidly established itself as a leading Italian company in the fields of Life Sciences and Public Health. Over the years it built a reputation as a highly qualified and trusted international partner, delivering bioanalytical and central laboratory services, innovation, and reliability to clients and stakeholders worldwide. The company's scientific foundation lies in immunology and vaccine development. Its core business grew around serological and cell-mediated immunity assays to evaluate the immunogenicity of vaccines, the creation and validation of bioanalytical methods, and the optimization of experimental protocols for the assessment of biologicals and therapeutic molecules. Tests conducted within VisMederi's facilities are routinely validated and standardized to ensure robust, high-quality protocols applicable to both clinical trial and research settings. As it expanded, VisMederi added specialized central laboratory services supporting immunogenicity and efficacy programs for vaccines and therapeutics, positioning itself as a focused laboratory partner for multicentre studies. Laboratory activities are performed in fully equipped BSL2, BSL2+, and BSL3 environments, enabling comprehensive bioanalytical services that meet high scientific and regulatory standards. The company operates under a certified Quality Management System and GCLP standards, developing, validating, and performing assays in alignment with EMA, FDA, and PMDA expectations. VisMederi describes itself as rooted in Siena while reaching the world, serving pharmaceutical and biotech partners across all stages of the product lifecycle, from pre-clinical studies through Clinical Phases I–IV. Its leadership includes founder Emanuele Montomoli as Chief Scientific Officer and Duccio Meiattini as Chief Executive Officer. The company continues to advance public health through scientific excellence, guided by its motto "We prove. You improve."

• 2009

  Founded in June 2009 as a spin-off of the Department of Molecular Medicine at the University of Siena.

Globally competent, science-driven research and service company partnering with the pharmaceutical industry to accelerate licensure of safer, more effective drugs, with regulatory-ready data aligned to EMA, FDA, and PMDA expectations.

• Bioanalytical Laboratory Services

  Clinical and pre-clinical sample testing for the evaluation of vaccines, monoclonal antibodies, and antiviral therapeutics across all stages of drug development.

• Central Laboratory

  Specialized central laboratory services supporting immunogenicity and efficacy programs for vaccines and therapeutics across multicentre studies.

• Serological and cell-mediated immunity assays

  Advanced assays to evaluate the immunogenicity of vaccines.

• Bioanalytical method development and validation

  Creation and validation of bioanalytical methods and optimization of experimental protocols for biologicals and therapeutic molecules.

1. 1Bioanalytical & Central Laboratory Services | VisMederivismederi.com
2. 2Company profile - VisMederivismederi.com
3. 3People - VisMederivismederi.com
4. 4VisMederi - Wikidatawikidata.org